Hepatitis Monthly

Published by: Kowsar

Development of a Chemiluminescence Immunoassay for Serum YB-1 and its Clinical Application as a Potential Diagnostic Marker for Hepatocellular Carcinoma

Li Pu 1 , Shi Jing 2 , Guo Bianqin 1 , Liu Ping 1 , Liang Qindong 1 , Liu Chenggui 1 , Cheng Feng 1 , Kuang Wenbin 1 , Wang Qin 1 , Dong Jinyu 1 , Xia Qianfeng 3 , Liu Yu 4 and Tu Zhiguang 1 , *
Authors Information
1 Key Laboratory of Clinical Laboratory Diagnostics, College of Laboratory Medicine, Chongqing Medical University, Chongqing, China
2 Department of Clinical Laboratory, The First Affiliated Hospital, Chongqing Medical University, Chongqing, China
3 Department of Laboratory Medicine, Hainan Medical College, Hainan, China
4 Department of Clinical Laboratory, Chongqing Tumor Hospital, Chongqing, China
Article information
  • Hepatitis Monthly: July 2013, 13 (7); e8918
  • Published Online: July 3, 2013
  • Article Type: Research Article
  • Received: November 1, 2012
  • Revised: January 14, 2013
  • Accepted: January 24, 2013
  • DOI: 10.5812/hepatmon.8918

To Cite: Pu L, Jing S, Bianqin G, Ping L, Qindong L, et al. Development of a Chemiluminescence Immunoassay for Serum YB-1 and its Clinical Application as a Potential Diagnostic Marker for Hepatocellular Carcinoma, Hepat Mon. 2013 ;13(7):e8918. doi: 10.5812/hepatmon.8918.

Abstract
Copyright: Copyright © 2013, Hepatitis Monthly. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited..
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Diamandis EP, Hoffman BR, Sturgeon CM. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for the Use of Tumor Markers. Clin Chem. 2008; 54(11): 1935-9[DOI][PubMed]
  • 2. Bertino G, Ardiri A, Malaguarnera M, Malaguarnera G, Bertino N, Calvagno GS. Hepatocellualar carcinoma serum markers. Semin Oncol. 2012; 39(4): 410-33[DOI][PubMed]
  • 3. Shen Q, Fan J, Yang XR, Tan Y, Zhao W, Xu Y, et al. Serum DKK1 as a protein biomarker for the diagnosis of hepatocellular carcinoma: a large-scale, multicentre study. Lancet Oncol. 2012; 13(8): 817-26[DOI][PubMed]
  • 4. Kohno K, Izumi H, Uchiumi T, Ashizuka M, Kuwano M. The pleiotropic functions of the Y-box-binding protein, YB-1. Bioessays. 2003; 25(7): 691-8[DOI][PubMed]
  • 5. En-Nia A, Yilmaz E, Klinge U, Lovett DH, Stefanidis I, Mertens PR. Transcription factor YB-1 mediates DNA polymerase alpha gene expression. J Biol Chem. 2005; 280(9): 7702-11[DOI][PubMed]
  • 6. Wu J, Lee C, Yokom D, Jiang H, Cheang MC, Yorida E, et al. Disruption of the Y-box binding protein-1 results in suppression of the epidermal growth factor receptor and HER-2. Cancer Res. 2006; 66(9): 4872-9[DOI][PubMed]
  • 7. Tay WL, Yip GW, Tan PH, Matsumoto K, Yeo R, Ng TP, et al. Y-Box-binding protein-1 is a promising predictive marker of radioresistance and chemoradioresistance in nasopharyngeal cancer. Mod Pathol. 2009; 22(2): 282-90[DOI][PubMed]
  • 8. Wachowiak R, Thieltges S, Rawnaq T, Kaifi JT, Fiegel H, Metzger R, et al. Y-box-binding protein-1 is a potential novel tumour marker for neuroblastoma. Anticancer Res. 2010; 30(4): 1239-42[PubMed]
  • 9. Kuwano M, Oda Y, Izumi H, Yang SJ, Uchiumi T, Iwamoto Y, et al. The role of nuclear Y-box binding protein 1 as a global marker in drug resistance. Mol Cancer Ther. 2004; 3(11): 1485-92[PubMed]
  • 10. Bargou RC, Jurchott K, Wagener C, Bergmann S, Metzner S, Bommert K, et al. Nuclear localization and increased levels of transcription factor YB-1 in primary human breast cancers are associated with intrinsic MDR1 gene expression. Nat Med. 1997; 3(4): 447-50[PubMed]
  • 11. Dhillon J, Astanehe A, Lee C, Fotovati A, Hu K, Dunn SE. The expression of activated Y-box binding protein-1 serine 102 mediates trastuzumab resistance in breast cancer cells by increasing CD44+ cells. Oncogene. 2010; 29(47): 6294-300[DOI][PubMed]
  • 12. Janz M, Harbeck N, Dettmar P, Berger U, Schmidt A, Jurchott K, et al. Y-box factor YB-1 predicts drug resistance and patient outcome in breast cancer independent of clinically relevant tumor biologic factors HER2, uPA and PAI-1. Int J Cancer. 2002; 97(3): 278-82[PubMed]
  • 13. Shibahara K, Sugio K, Osaki T, Uchiumi T, Maehara Y, Kohno K, et al. Nuclear expression of the Y-box binding protein, YB-1, as a novel marker of disease progression in non-small cell lung cancer. Clin Cancer Res. 2001; 7(10): 3151-5[PubMed]
  • 14. Das S, Chattopadhyay R, Bhakat KK, Boldogh I, Kohno K, Prasad R, et al. Stimulation of NEIL2-mediated oxidized base excision repair via YB-1 interaction during oxidative stress. J Biol Chem. 2007; 282(39): 28474-84[DOI][PubMed]
  • 15. Shiota M, Zoubeidi A, Kumano M, Beraldi E, Naito S, Nelson CC, et al. Clusterin is a critical downstream mediator of stress-induced YB-1 transactivation in prostate cancer. Mol Cancer Res. 2011; 9(12): 1755-66[DOI][PubMed]
  • 16. Szczuraszek K, Halon A, Materna V, Mazur G, Wrobel T, Kuliczkowski K, et al. Elevated YB-1 expression is a new unfavorable prognostic factor in non-Hodgkin's lymphomas. Anticancer Res. 2011; 31(9): 2963-70[PubMed]
  • 17. Frye BC, Halfter S, Djudjaj S, Muehlenberg P, Weber S, Raffetseder U, et al. Y-box protein-1 is actively secreted through a non-classical pathway and acts as an extracellular mitogen. EMBO Rep. 2009; 10(7): 783-9[DOI][PubMed]
  • 18. Tacke F, Kanig N, En-Nia A, Kaehne T, Eberhardt CS, Shpacovitch V, et al. Y-box protein-1/p18 fragment identifies malignancies in patients with chronic liver disease. BMC Cancer. 2011; 11: 185[DOI][PubMed]
  • 19. Kuwano M, Uchiumi T, Hayakawa H, Ono M, Wada M, Izumi H, et al. The basic and clinical implications of ABC transporters, Y-box-binding protein-1 (YB-1) and angiogenesis-related factors in human malignancies. Cancer Sci. 2003; 94(1): 9-14[PubMed]
  • 20. Graslund S, Nordlund P, Weigelt J, Hallberg BM, Bray J, Gileadi O, et al. Protein production and purification. Nat Methods. 2008; 5(2): 135-46[DOI][PubMed]
  • 21. Norwood TH, Zeigler CJ, Martin GM. Dimethyl sulfoxide enhances polyethylene glycol-mediated somatic cell fusion. Somatic Cell Genet. 1976; 2(3): 263-70[PubMed]
  • 22. Powers DM. Interference Testing in Clinical Chemistry: Approved Guideline. 2002;
  • 23. Tholen DW. Evaluation of the Linearity of Quantitative Measurement Procedures: A Statistical Approach, Approved Guideline. 2003;
  • 24. Tholen DW. Evaluation of Precision Performance of Quantitative Measurement Methods: Approved Guideline. 2004;
  • 25. Raffetseder U, Rauen T, Boor P, Ostendorf T, Hanssen L, Floege J, et al. Extracellular YB-1 blockade in experimental nephritis upregulates Notch-3 receptor expression and signaling. Nephron Exp Nephrol. 2011; 118(4)-8[DOI][PubMed]
  • 26. Rauen T, Raffetseder U, Frye BC, Djudjaj S, Muhlenberg PJ, Eitner F, et al. YB-1 acts as a ligand for Notch-3 receptors and modulates receptor activation. J Biol Chem. 2009; 284(39): 26928-40[DOI][PubMed]
  • 27. Giovannini C, Gramantieri L, Chieco P, Minguzzi M, Lago F, Pianetti S, et al. Selective ablation of Notch3 in HCC enhances doxorubicin's death promoting effect by a p53 dependent mechanism. J Hepatol. 2009; 50(5): 969-79[DOI][PubMed]
  • 28. Giovannini C, Lacchini M, Gramantieri L, Chieco P, Bolondi L. Notch3 intracellular domain accumulates in HepG2 cell line. Anticancer Res. 2006; 26(3A): 2123-7[PubMed]
  • 29. Haruki N, Kawaguchi KS, Eichenberger S, Massion PP, Olson S, Gonzalez A, et al. Dominant-negative Notch3 receptor inhibits mitogen-activated protein kinase pathway and the growth of human lung cancers. Cancer Res. 2005; 65(9): 3555-61[DOI][PubMed]
  • 30. Konishi J, Kawaguchi KS, Vo H, Haruki N, Gonzalez A, Carbone DP, et al. Gamma-secretase inhibitor prevents Notch3 activation and reduces proliferation in human lung cancers. Cancer Res. 2007; 67(17): 8051-7[DOI][PubMed]
  • 31. Serafin V, Persano L, Moserle L, Esposito G, Ghisi M, Curtarello M, et al. Notch3 signalling promotes tumour growth in colorectal cancer. J Pathol. 2011; 224(4): 448-60[DOI][PubMed]
  • 32. Bergmann S, Royer-Pokora B, Fietze E, Jurchott K, Hildebrandt B, Trost D, et al. YB-1 provokes breast cancer through the induction of chromosomal instability that emerges from mitotic failure and centrosome amplification. Cancer Res. 2005; 65(10): 4078-87[DOI][PubMed]
  • 33. Gimenez-Bonafe P, Fedoruk MN, Whitmore TG, Akbari M, Ralph JL, Ettinger S, et al. YB-1 is upregulated during prostate cancer tumor progression and increases P-glycoprotein activity. Prostate. 2004; 59(3): 337-49[DOI][PubMed]
  • 34. Huang X, Ushijima K, Komai K, Takemoto Y, Motoshima S, Kamura T, et al. Co-expression of Y box-binding protein-1 and P-glycoprotein as a prognostic marker for survival in epithelial ovarian cancer. Gynecol Oncol. 2004; 93(2): 287-91[DOI][PubMed]
  • 35. Oda Y, Sakamoto A, Shinohara N, Ohga T, Uchiumi T, Kohno K, et al. Nuclear expression of YB-1 protein correlates with P-glycoprotein expression in human osteosarcoma. Clin Cancer Res. 1998; 4(9): 2273-7[PubMed]
  • 36. Saji H, Toi M, Saji S, Koike M, Kohno K, Kuwano M. Nuclear expression of YB-1 protein correlates with P-glycoprotein expression in human breast carcinoma. Cancer Lett. 2003; 190(2): 191-7[PubMed]
  • 37. Yang JY, Ha SA, Yang YS, Kim JW. p-Glycoprotein ABCB5 and YB-1 expression plays a role in increased heterogeneity of breast cancer cells: correlations with cell fusion and doxorubicin resistance. BMC Cancer. 2010; 10: 388[DOI][PubMed]
  • 38. Yasen M, Kajino K, Kano S, Tobita H, Yamamoto J, Uchiumi T, et al. The up-regulation of Y-box binding proteins (DNA binding protein A and Y-box binding protein-1) as prognostic markers of hepatocellular carcinoma. Clin Cancer Res. 2005; 11(20): 7354-61[DOI][PubMed]
  • 39. Habibi G, Leung S, Law JH, Gelmon K, Masoudi H, Turbin D, et al. Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes. Breast Cancer Res. 2008; 10(5)[DOI][PubMed]
  • 40. Huang J, Tan PH, Li KB, Matsumoto K, Tsujimoto M, Bay BH. Y-box binding protein, YB-1, as a marker of tumor aggressiveness and response to adjuvant chemotherapy in breast cancer. Int J Oncol. 2005; 26(3): 607-13[PubMed]
  • 41. Jurchott K, Kuban RJ, Krech T, Bluthgen N, Stein U, Walther W, et al. Identification of Y-box binding protein 1 as a core regulator of MEK/ERK pathway-dependent gene signatures in colorectal cancer cells. PLoS Genet. 2010; 6(12)[DOI][PubMed]
  • 42. To K, Zhao Y, Jiang H, Hu K, Wang M, Wu J, et al. The phosphoinositide-dependent kinase-1 inhibitor 2-amino-N-[4-[5-(2-phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-ace tamide (OSU-03012) prevents Y-box binding protein-1 from inducing epidermal growth factor receptor. Mol Pharmacol. 2007; 72(3): 641-52[DOI][PubMed]
  • 43. Chaudhary PM, Roninson IB. Induction of multidrug resistance in human cells by transient exposure to different chemotherapeutic drugs. J Natl Cancer Inst. 1993; 85(8): 632-9[PubMed]
  • 44. Gluz O, Mengele K, Schmitt M, Kates R, Diallo-Danebrock R, Neff F, et al. Y-box-binding protein YB-1 identifies high-risk patients with primary breast cancer benefiting from rapidly cycled tandem high-dose adjuvant chemotherapy. J Clin Oncol. 2009; 27(36): 6144-51[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader